These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 30093560

  • 1. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
    Zhang FL, Cao JL, Xie HY, Sun R, Yang LF, Shao ZM, Li DQ.
    Cancer Res; 2018 Oct 15; 78(20):5780-5792. PubMed ID: 30093560
    [Abstract] [Full Text] [Related]

  • 2. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.
    Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, Reinke LM, Peter ME, Feng Y, Gius D, Siziopikou KP, Peng J, Xiao X, Cheng C.
    Genes Dev; 2014 Jun 01; 28(11):1191-203. PubMed ID: 24840202
    [Abstract] [Full Text] [Related]

  • 3. Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.
    Harvey SE, Xu Y, Lin X, Gao XD, Qiu Y, Ahn J, Xiao X, Cheng C.
    RNA; 2018 Oct 01; 24(10):1326-1338. PubMed ID: 30042172
    [Abstract] [Full Text] [Related]

  • 4. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
    Chen Q, Gu M, Cai ZK, Zhao H, Sun SC, Liu C, Zhan M, Chen YB, Wang Z.
    Cell Mol Life Sci; 2021 Feb 01; 78(3):949-962. PubMed ID: 32440711
    [Abstract] [Full Text] [Related]

  • 5. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases.
    Sun H, Liu T, Zhu D, Dong X, Liu F, Liang X, Chen C, Shao B, Wang M, Wang Y.
    Genes Chromosomes Cancer; 2017 Aug 01; 56(8):598-607. PubMed ID: 28393427
    [Abstract] [Full Text] [Related]

  • 6. MORC2 regulates RBM39-mediated CDK5RAP2 alternative splicing to promote EMT and metastasis in colon cancer.
    He Y, Shao Y, Zhou Z, Li T, Gao Y, Liu X, Yuan G, Yang G, Zhang L, Li F.
    Cell Death Dis; 2024 Jul 24; 15(7):530. PubMed ID: 39048555
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1.
    Liao XH, Zhang Y, Dong WJ, Shao ZM, Li DQ.
    Oncotarget; 2017 Nov 17; 8(58):97941-97954. PubMed ID: 29228664
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
    Ling Y, Cao Q, Liu Y, Zhao J, Zhao Y, Li K, Chen Z, Du X, Huo X, Kang H, Chen Z.
    Breast Cancer; 2021 Mar 17; 28(2):368-378. PubMed ID: 33047272
    [Abstract] [Full Text] [Related]

  • 14. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
    Bhattacharya R, Mitra T, Ray Chaudhuri S, Roy SS.
    J Cell Biochem; 2018 Apr 17; 119(4):3373-3383. PubMed ID: 29130517
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G, Chiodoni C, Shen F, Cattelani S, Soliera AR, Manzotti G, Grisendi G, Dominici M, Rivasi F, Colombo MP, Fatatis A, Calabretta B.
    Neoplasia; 2014 Dec 17; 16(12):1047-58. PubMed ID: 25499218
    [Abstract] [Full Text] [Related]

  • 17. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Wang PS, Chou CH, Lin CH, Yao YC, Cheng HC, Li HY, Chuang YC, Yang CN, Ger LP, Chen YC, Lin FC, Shen TL, Hsiao M, Lu PJ.
    Oncogene; 2018 Aug 17; 37(34):4662-4678. PubMed ID: 29755127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H, Sang M, Liu F, Ai N, Geng C.
    Pathol Res Pract; 2019 Apr 17; 215(4):697-704. PubMed ID: 30611621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.